17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
The long-rumored acquisition of US biotech Seagen was finally announced in March, albeit it was not long-time suitor Merck & Co behind the deal, but rather fellow US pharma giant Pfizer. 4 April 2023
Spanish epigenetics firm Oryzon Genomics has announced encouraging results from a planned interim analysis of the Phase IIb PORTICO study. 4 April 2023
Dermatology company Botanix Pharmaceuticals has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide. 4 April 2023
The administrators of the USA’s public insurance scheme, Medicare, are getting ready to implement the measures included in the Inflation Reduction Act. 4 April 2023
Shares in Sweden’s Asarina Pharma looked set to close more than 2% higher based on results from its Phase IIa study of the endogenous neurosteroid sepranolone for the treatment of Tourette syndrome. 3 April 2023
Japanese drugmaker Eisai (TYO: 4523) has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor Tazverik (tazemetostat hydrobromide) based on “Patient-Proposed Healthcare Services” system, which will be conducted by the National Cancer Center Hospital. 3 April 2023
Karim Mikhail is to resign as president and chief executive of Amarin Corp, the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing. 3 April 2023
The COVID-19 pandemic brought into the spotlight, at European level and particularly in Greece, the gaps in the national health systems, which are mainly due to underfunding and long-standing distortions, commented the Hellenic Association of Pharmaceutical Companies (SFEE). 3 April 2023
The Irish Minister of International Development and Diaspora, Sean Fleming, visited Brazil’s research institute Fiocruz last month to discuss partnership projects between the country and Fiocruz. 3 April 2023
Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients. 31 March 2023
Draft EU regulatory proposals have been described by the leading European trade body as “sabotage” of the industry. We consider the fallout with Maarten Meulenbelt, partner and expert on EU regulatory affairs at Sidley Austin. 31 March 2023
US healthcare giant Johnson & Johnson has made the bold move of halting its investigational respiratory syncytial virus (RSV) adult vaccine program and discontinuing its Phase III EVERGREEN study. 30 March 2023
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year. 29 March 2023
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
US clinical-stage biopharma company Viking Therapeutics saw its shares close up nearly 70% at $15.44 yesterday, after it released encouraging early-stage data on its obesity candidate VK2735. 29 March 2023
Covant Therapeutics, a Boston, USA-based covalent drug discovery company that was incubated by Roivant Sciences, has entered into an exclusive research collaboration and worldwide licensing agreement with German family-owned pharma major Boehringer Ingelheim covering Covant’s ADAR1 program. 29 March 2023
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.